ArticleFrontiers in oncology2026
Efficacy and safety of hypofractionated radiotherapy for melanoma brain metastases: a retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Melanoma brain metastasis (MBM) is associated with a poor prognosis and a high risk of intracranial hemorrhage (ICH), which may complicate the use of stereotactic radiosurgery (SRS). This study evaluated the efficacy and safety of hypofractionated radiotherapy (HFRT) for MBM, with a specific focus on metastases with hemorrhagic components. Patients and methods: In this single-center retrospective study, 26 patients with MBMs received HRT regimens of 30 Gy/5 fractions, 36 Gy/6 fractions, or 42 Gy/7 fractions. The primary endpoint was the local control (LC) rate assessed on the first MRI evaluation after radiotherapy completion (1-3 months after radiotherapy completion). Secondary endpoints included intracranial progression-free survival (IPFS), overall survival (OS), and treatment-related adverse events (AEs). Results: The disease control rate was 96% at the 3-month assessment (2 complete responses, 16 partial responses, 7 stable disease). The median OS was 10.5 months and the median IPFS was 4.5 months. No grade ≥3 AEs or symptomatic radiation necrosis occurred during the follow-up period (median 7.5 months). Notably, no radiotherapy-related ICH or exacerbation of pre-existing hemorrhage was observed, and hemorrhage reduction was achieved in all 11 patients with baseline ICH (100%). Conclusion: HFRT demonstrated promising local control and a favorable safety profile in this cohort of MBM patients, It shows particular potential for treating hemorrhagic metastases and may offer a valuable alternative to SRS in selected high-risk scenarios, meriting further investigation in larger studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.